Prostate Cancer Information from the National Cancer Institute
Prostate cancer is the most common cancer, excluding skin cancer, and the second leading cause of cancer-related death in men in the United States. African American men have higher incidence and at least double the mortality rates compared with men of other racial and ethnic groups.
Prostate cancer incidence rates rose dramatically in the late 1980s. This increase reflects improvements in detection and diagnosis through widespread use of prostate-specific antigen (PSA) testing, which received initial U.S. Food and Drug Administration approval in 1986. Since the early 1990s, prostate cancer incidence has been declining. Mortality rates for prostate cancer have also declined since the early 1990s. Read more at the National Cancer Institute, National Institutes of Health.
Information on Prostate Cancer from Memorial Sloan-Kettering Cancer Center
In this section, you can find information about treating patients with prostate cancer, the services for patients with prostate cancer, and prostate cancer research under way at Memorial Sloan-Kettering Cancer Center.
Tracking Your PSA Result
A 1 min. 34 sec. narrated slide show on prostate cancer from the MD Anderson Cancer Clinic.
Quiz: Test Your Prostate Cancer Knowledge
Take the quiz at the Cleveland Clinic.
Risk Assessment
The risk assessment quiz was designed to help men, step by step, figure out their risk of developing the disease. Simply answer each question to the best of your knowledge and wait to see your results at the end of the quiz. Presented by Prostate Cancer Canada.
News Release: Major Statin Study Reveals Several Important Findings for Reducing Prostate Cancer and Disease
Sunday, April 26, 2009 ROCHESTER, Minn. — Statins, drugs widely prescribed to lower cholesterol, may have protective effects on prostate health. This large Mayo Clinic cohort study looked at three different aspects of urological health — prostate cancer, erectile dysfunction and prostate enlargement. Initial research results are being presented April 25–30, 2009, at the American Urological Association (AUA) meeting in Chicago. Read more from the Mayo Clinic.
Video: What Every Man Need to Know
Video resource on prostate cancer and treatments from the James Buchanan Brady urological Institute at Johns Hopkins Medical.
Video: Prostatectomy Hospital Stay and Recuperation
Video resource on prostate cancer and treatments from the James Buchanan Brady urological Institute at Johns Hopkins Medical.
Video: Radical Retropubic Prostatectomy
Illustrations and video footage, of an open surgical technique that demonstrates the value of both visual and tactile assessment in performing the best cancer operation while being able to preserve quality of life from Johns Hopkins Medicine.
Podcast: Prostate Cancer
This podcast – featuring prostate cancer expert Dr. Anthony D’Amico, Chief of Genitourinary Radiation Oncology at Brigham and Women’s Hospital and Chief, Prostate Cancer Radiation Oncology Service at Dana-Farber/Brigham and Women’s Cancer Center – will answer commonly asked questions. Listen at the BWH website.
Video: Advances in the Treatment of Prostate Cancer
A 1 hour long webcast discussing recent advances in prostate cancer treatments including proton beam radiation, minimally invasive surgery, and robotic surgery from the MD Anderson Cancer Clinic.
Prostate Cancer Treatment-overview; localized; advanced
The NCCN Treatment Summaries for People with Cancer™ are designed to give patients with cancer a better understanding of cancer, including diagnosis and treatment options, so they can work with their health care providers to achieve longer and better-quality lives. The NCCN Treatment Summaries are based on the NCCN Clinical Practice Guidelines in Oncology™— treatment recommendations most widely used by oncologists and other cancer care providers in the U.S. and the world. The NCCN Guidelines combine the best available medical evidence with expert experience on 97% of the cancers that affect people and are continually updated. See prostate cancer-related National Comprehensive Cancer Network Treatment Summaries for People with Cancer. (Free registration required to access)
NCCN Clinical Practice Guidelines in Oncology
The NCCN Clinical Practice Guidelines in Oncology™ – the recognized standard for clinical policy in oncology – are the most comprehensive and most frequently updated clinical practice guidelines available in any area of medicine. Covering 97 percent of all patients with cancer and updated on a continual basis, the NCCN Guidelines are developed through an explicit review of the evidence integrated with expert medical judgment by multidisciplinary panels from NCCN Member Institutions." Read clinical practice guidelines for healthcare professionals from the National Comprehensive Cancer Network.
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Key Question 1: Does screening for prostate cancer with prostate-specific antigen (PSA), as a single-threshold test or as a function of multiple tests over time, decrease morbidity or mortality? Key Question 2: What are the magnitude and nature of harms associated with prostate cancer screening other than overtreatment? Key Question 3: What is the natural history of PSA-detected, non-palpable, localized prostate cancer? See National Guideline Clearinghouse major recommendations.
Abstract: Screening and prostate-cancer mortality in a randomized European study.
BACKGROUND: The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer. METHODS: We identified 182,000 men between the ages of 50 and 74 years through registries in seven European countries for inclusion in our study. The men were randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening. The predefined core age group for this study included 162,243 men between the ages of 55 and 69 years. The primary outcome was the rate of death from prostate cancer. Full text available free through PubMed.
Abstract: Prostate Specific Antigen Best Practice Statement: 2009 Update.
PURPOSE: We provide current information on the use of PSA testing for the evaluation of men at risk for prostate cancer, and the risks and benefits of early detection. MATERIALS AND METHODS: The report is a summary of the American Urological Association PSA Best Practice Policy 2009. The summary statement is based on a review of the current professional literature, clinical experience and the expert opinions of a multispecialty panel. It is intended to serve as a resource for physicians, other health care professionals, and patients. See Abstract at PubMed.
Abstract: Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: A systematic review.
BACKGROUND AND PURPOSE: For the radiation treatment of prostate cancer high dose should be delivered for optimal biochemical control. Treatment can be given by dose-escalated external beam radiotherapy (EBRT) or external beam radiotherapy combined with a radioactive seed implantation (EBSeeds) or high-dose rate (HDR) brachytherapy (EBTI). Differences in outcome between the modalities were assessed by a systematic review. See Abstract at PubMed.
Abstract: New treatments for localized prostate cancer.
Interest in focal therapy for prostate cancer has recently been renewed owing to downward stage migration, improved biopsy and imaging techniques, and the prevalence of either unifocal cancer or a dominant cancer with secondary tumors of minimal malignant potential. Several techniques have potential for focal ablation of prostate cancer. See Abstract at PubMed
Abstract: Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons.
PURPOSE: With the exponential growth of robotic urological surgery, particularly with robot assisted radical prostatectomy, guidelines for safe initiation of this technology are a necessity. Currently no standardized credentialing system exists to our knowledge to evaluate surgeon competency and safety with robotic urological surgery performance. See Abstract at PubMed
Abstract: Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
PURPOSE: The development of erectile dysfunction represents a major concern for potent men with localized prostate cancer undergoing open radical retropubic prostatectomy. We identified factors predicting the preservation of erectile function in men undergoing open radical retropubic prostatectomy. See Abstract at PubMed
Abstract: A systematic review of the effect of diet in prostate cancer prevention and treatment.
Dietary therapy has been proposed as a cost effective and noninvasive means of reducing the risk of prostate cancer (PC) and its progression. There is a large
volume of published studies describing the role of diet in the prevention and treatment of PC. This article systematically reviews the data for dietary-based therapy in the prevention of PC, as well as in the management of patients with PC, aiming to provide clarity surrounding the role of diet in preventing and treating PC. Full text available free through PubMed.
Abstract: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
Bisphosphonates might modulate the development of symptomatic bone metastases in men with prostate cancer. The Medical Research Council (MRC) PR05 and PR04 randomised controlled trials assessed the use of sodium clodronate, an oral, first-generation bisphosphonate. We report the final analyses of long-term survival data with additional follow-up in both trials. Full text available free through PubMed.
Looking for a Top-Rated
Urologist or Therapeutic Radiologist?
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors
To find out who the top doctors are around the country, nonprofit Consumers' CHECKBOOK surveyed roughly 340,000 physicians to tell us which specialists they would want to care for a loved one. The Top Doctors database contains the names of over 23,000 doctors who were mentioned most often. Find top-rated doctors in the fifty largest metropolitan areas, in over thirty-five specialties, and more.
Digital Rectal Prostate Exam
Source: National Cancer Institute
Prostate Cancer Awareness Month is September
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors in over 30 specialties.
Search Top Doctors
database of 23,000 top-rated physicians by
Doctor's Name
Search Top
Doctors database of 23,000 top-rated
physicians by Specialty
Prostate cancer patients - their stories.
Understanding the Puzzle (click the image to evaluate your own prostate cancer risk)
Source: National Cancer Institute
Consumers' Guide to Hospitals
Which Hospital Should You Choose
"What makes the Consumers' Guide to Hospitals so special?
We've got 30 million answers to that question. That's how many hospital records Consumers' CHECKBOOK sifted through to calculate risk-adjusted death rates and adverse-outcome rates, and that's just part of the data used to rate the hospitals. The organization also sent out more than 280,000 questionnaires to physicians in 53 major metropolitan areas in the United States, asking them to rate their local hospitals; checked ratings of the hospitals by surveyed consumers; checked which hospitals were providing recommended tests and procedures for patients with specified medical problems; and more."
AARP The Magazine
